Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 4/20 | 0.37 |
| ▸ | THRB | P10828 | 8/20 | 0.34 |
| ▸ | MEN1 | O00255 | 6/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.34 |
| ▸ | LMNA | P02545 | 5/20 | 0.34 |
| ▸ | BLM | P54132 | 4/20 | 0.34 |
| ▸ | THRA | P10827 | 4/20 | 0.34 |
| ▸ | PPARG | P37231 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.34 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | GABRP | O00591 | 1/20 | 0.34 |
| ▸ | GABRD | O14764 | 1/20 | 0.34 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | PCNA | P12004 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1742705 | 0.89 | THRB (0.45) | THRBMEN1KMT2ALMNABLM | |
| SCHEMBL1274573 | 0.89 | THRB (0.45) | THRBMEN1KMT2ALMNABLM | |
| SCHEMBL9498158 | 0.81 | — | — | |
| SCHEMBL11742941 | 0.80 | THRB (0.42) | THRBMEN1KMT2ALMNABLM | |
| SCHEMBL4926007 | 0.79 | THRB (0.41) | THRBMEN1KMT2ALMNABLM | |
| SCHEMBL16671244 | 0.78 | PTPRA (0.38) | THRBMEN1KMT2ALMNABLM | |
| SCHEMBL169323 | 0.77 | LMNA (0.54) | THRBMEN1KMT2ALMNABLM | |
| SCHEMBL5319562 | 0.77 | LMNA (0.54) | THRBMEN1KMT2ALMNABLM | |
| SCHEMBL230513 | 0.74 | KMT2A (0.52) | THRBMEN1KMT2ALMNABLM | |
| SCHEMBL282065 | 0.74 | KMT2A (0.52) | THRBMEN1KMT2ALMNABLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040156859-A1 | GP-41 peptides, BBB peptides, anticancer agents, antihistamines, bronchodilators, hypotensive agents, antiangina agents, opioids, analgesics, antidepressants, and hypothyroid agents reactive with amino, hydroxyl or thiol groups | CONJUCHEM, INC. (CA) | 2004-08-12 | — | — | US | claimed |
| US-6706892-B1 | ADMINSTERING MALEIMIDE DERIVATIVE TO COVALENTLY BOND PROTEIN; WOUND HEALING, ANTIBIOTIC, ANTIINFLAMMATORY, ANTICARCINOGENIC, HYPOTENSIVE, AND ANALGESIC AGENTS | CONJUCHEM, INC. (CA) | 2004-03-16 | — | — | US | claimed |
| EP-1235618-A2 | BIOCONJUGATION IN VIVO TO PULMONARY OR BLOOD COMPONENTS | Conjuchem, Inc. (CA) | 2002-09-04 | — | — | EP | claimed |
| WO-2001017568-A2 | BIOCONJUGATION IN VIVO TO PULMONARY OR BLOOD COMPONENTS | CONJUCHEM, INC. (CA) | 2001-03-15 | — | — | WO | claimed |
| US-20040156859-A1 | GP-41 peptides, BBB peptides, anticancer agents, antihistamines, bronchodilators, hypotensive agents, antiangina agents, opioids, analgesics, antidepressants, and hypothyroid agents reactive with amino, hydroxyl or thiol groups | CONJUCHEM, INC. (CA) | 2004-08-12 | — | — | US | disclosed |
| US-6706892-B1 | ADMINSTERING MALEIMIDE DERIVATIVE TO COVALENTLY BOND PROTEIN; WOUND HEALING, ANTIBIOTIC, ANTIINFLAMMATORY, ANTICARCINOGENIC, HYPOTENSIVE, AND ANALGESIC AGENTS | CONJUCHEM, INC. (CA) | 2004-03-16 | — | — | US | disclosed |
| EP-1235618-A2 | BIOCONJUGATION IN VIVO TO PULMONARY OR BLOOD COMPONENTS | Conjuchem, Inc. (CA) | 2002-09-04 | — | — | EP | disclosed |
| WO-2001017568-A2 | BIOCONJUGATION IN VIVO TO PULMONARY OR BLOOD COMPONENTS | CONJUCHEM, INC. (CA) | 2001-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040156859-A1 | GP-41 peptides, BBB peptides, anticancer agents, antihistamines, bronchodilators, hypotensive agents, antiangina agents, opioids, analgesics, antidepressants, and hypothyroid agents reactive with amino, hydroxyl or thiol groups | OGFR, HDGF, SERPINA6 | SCN9A 2659/4885THRB 124/4885MEN1 4065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.